FRA | Jotup

Prospera Energy Inc. Secures $3.5 Million in Development Financing and Announces Strategic Appointments to Strengthen Leadership Team

Retrieved on:

Tuesday, December 5, 2023

Agreement, PEI, Sale, FRA, ESG, Barrel, OTC, Natural gas

Accordingly, PEI anticipates achieving 2023 year-end exit rate of 1,800 boepd

Key Points:

Accordingly, PEI anticipates achieving 2023 year-end exit rate of 1,800 boepd
Prospera Energy Inc. is pleased to announce the successful completion of a $3,000,000 GORR financing.
The funds from the transaction will be used to conduct the horizontal well development program on the Company’s Cuthbert properties.
As a part of White Tundra's business development initiatives supporting Prospera, Shubham Garg assisted in coordinating the placement with the investor group.
Additionally, Prospera Energy announces a clarification to the closing of its private placement, as a total of $583,000 was raised (previously $580,000 was announced).

Standard Lithium to Participate in December Investor Conferences

Retrieved on:

Monday, December 4, 2023

Lithium, SLI, Bank, FRA, Bank of America, Deutsche Bank

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced its participation in the following virtual December investor conferences:

Key Points:

VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced its participation in the following virtual December investor conferences:
US Based Lithium Supply, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:15am PT
Company Presentation, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:30am PT
Management will be hosting one-on-one meetings during the conferences.
Interested investors should contact their Deutsche Bank or Bank of America representative or Standard Lithium Investor Relations at [email protected] .

Latitude Uranium Announces Final Batch of Assay Results, Including 2.88% U3O8 over 0.5m and 2.05% U3O8 over 0.5m from Angilak

Retrieved on:

Monday, December 4, 2023

Copper, LUR, Strike, FRA, OTCQB, Pulse, Proximity, Uranium mining

Known mineralization has been further extended, including hole 15 which returned 2.88% U3O8 over 0.5m and 2.05% U3O8 over 0.5m.

Key Points:

Known mineralization has been further extended, including hole 15 which returned 2.88% U3O8 over 0.5m and 2.05% U3O8 over 0.5m.
A new potential lens was discovered, increasing the known mineralization and adding to the potential for further expansion.
These findings will be synthesized over the winter months into a cohesive 2024 drill program for Angilak.
Additional geologic knowledge has been obtained and will be synthesized over the winter months into a robust 2024 drill program at Angilak.

Standard Lithium Provides Update on Phase 1A Commercialization Progress, Announces Engagement of Citi for Strategic Financing and Partnerships

Retrieved on:

Monday, December 4, 2023

Lithium, Dorado, DFS, BNP Paribas, DLE, Partnership, Department of the Treasury, LCE, LANXESS, CapeNature, FRA, Citigroup, Act, SLI, Smackover Formation, EV

The Company has engaged Citi to facilitate strategic financing and partnership options for the Phase 1A Project, as well as for advancing the broader South West Arkansas project and the Company’s initiatives in East Texas.

Key Points:

The Company has engaged Citi to facilitate strategic financing and partnership options for the Phase 1A Project, as well as for advancing the broader South West Arkansas project and the Company’s initiatives in East Texas.
In line with its strategic focus on core operations, LANXESS Corporation (“LANXESS”) has communicated its plans to commercialize its role in the Phase 1A Project alongside Standard Lithium.
These agreements will form the basis of the operational framework for the Phase 1A Project.
With the Phase 1A Project’s ownership and operational structure now clearly defined, Standard Lithium is well-placed to optimize project partnerships and structure off-take agreements that capture the full potential value of the project.

Standard Lithium Provides Update on Phase 1A Commercialization Progress, Announces Engagement of Citi for Strategic Financing and Partnerships

Retrieved on:

Monday, December 4, 2023

Lithium, Dorado, DFS, BNP Paribas, DLE, Partnership, Department of the Treasury, LCE, LANXESS, CapeNature, FRA, Citigroup, Act, SLI, Smackover Formation, EV

The Company has engaged Citi to facilitate strategic financing and partnership options for the Phase 1A Project, as well as for advancing the broader South West Arkansas project and the Company’s initiatives in East Texas.

Key Points:

The Company has engaged Citi to facilitate strategic financing and partnership options for the Phase 1A Project, as well as for advancing the broader South West Arkansas project and the Company’s initiatives in East Texas.
In line with its strategic focus on core operations, LANXESS Corporation (“LANXESS”) has communicated its plans to commercialize its role in the Phase 1A Project alongside Standard Lithium.
These agreements will form the basis of the operational framework for the Phase 1A Project.
With the Phase 1A Project’s ownership and operational structure now clearly defined, Standard Lithium is well-placed to optimize project partnerships and structure off-take agreements that capture the full potential value of the project.

New to The Street Announces Five Corporate Interviews, Episode 535, Airing on the FOX Business Network on Monday, December 4, 2023, at 10:30 PM PT

Retrieved on:

Friday, December 1, 2023

As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections.

Key Points:

As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections.
Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3.
The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results.
Phases 2a and 2b confirmed that the drug had success in 25 out of 26 patients, approximately 96% success with no reinfections.

Pan American Announces $2 Million Flow Through Unit Offering

Retrieved on:

Wednesday, November 29, 2023

Lithium, Income Tax Act, Sale, Indian stock exchange, Pan-American, FRA, Legislation, News, OTC, FT, Security (finance)

The FT Offering is in addition to the previously announced $3,000,000 private placement financing of units (“non-FT Units”) at a price of $0.40 per non-FT Unit (“non-FT Offering”).

Key Points:

The FT Offering is in addition to the previously announced $3,000,000 private placement financing of units (“non-FT Units”) at a price of $0.40 per non-FT Unit (“non-FT Offering”).
Subject to compliance with the policies of the Canadian Securities Exchange ("CSE") and applicable securities legislation, the Company may pay finder’s fees in connection with the FT Offering and non-FT Offering‎.
The Company anticipates closing of the FT Offering to occur on or about December 15, 2023.
The securities issued pursuant to the FT Offering will be subject to a four-month hold period from the closing date.

Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing

Retrieved on:

Tuesday, November 28, 2023

Psilocybin, ICH, Sale, API, Research, FRA, Reproduction, GMP, Health Canada, Pharmaceutical industry

The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, strengthening its position as a pioneering force in the psychedelic research and formulation space.

Key Points:

The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, strengthening its position as a pioneering force in the psychedelic research and formulation space.
Demonstrating its commitment to innovation and research, Optimi has cultivated these new Psilocybin-containing mushroom strains with the aim that they will play a pivotal role in the development of psilocybin extracts and novel drug candidates.
Optimi also announces the advancement of its full spectrum, GMP extract quality program.
The Company has successfully completed process validation for the natural psilocybin drug candidate, and the stability testing according to ICH guidelines is ongoing.

Irwin Naturals Reports Q3 2023 Financial Results

Retrieved on:

Tuesday, November 28, 2023

Serenity, CFO, Acquisition, Ketamine, FRA, THC, Investment, OTC, Pharmaceutical industry

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) reported its financial results for its third quarter of fiscal 2023, the period ended September 30, 2023, on www.sedar.com.

Key Points:

LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) reported its financial results for its third quarter of fiscal 2023, the period ended September 30, 2023, on www.sedar.com.
Income from operations decreased $2.9 million from $0.6 million in Q3 2022 to a loss of $2.3 million in Q3 2023.
The decrease is primarily attributed to the continued startup costs related to the Company’s 2022 and 2023 Acquisitions at Irwin Naturals Emergence.
Sold the assets of underperforming clinics and shifted its focus on the clinics wholly-owned and operated by Irwin Naturals Emergence.

Xtract One Technologies Selected by Community Health Network for Weapons Detection Services

Retrieved on:

Tuesday, November 28, 2023

Firearm, Community, Partnership, Health care, Community Behavioral Health, XTRA, Weapon, FRA, Hospital, Security, Community Hospital North, AI, Privacy, Community Howard Regional Health, Community Hospital East, TSX, Patient, Nursing

The system underwent a rigorous and successful 30-day pilot program at Community Hospital East, during which the technology demonstrated its effectiveness in detecting weapons.

Key Points:

The system underwent a rigorous and successful 30-day pilot program at Community Hospital East, during which the technology demonstrated its effectiveness in detecting weapons.
In collaboration with their partner, Indiana-based CK2 Technologies , Community has chosen Xtract One’s SmartGateway system to ensure weapons are not brought into hospitals within their network, and to ensure a safe and comforting environment for all patients, staff, and visitors.
During the pilot period, the Xtract One system successfully detected and alerted on weapons of all sizes, including firearms and pocketknives.
With Xtract One, we’re able to focus on our work delivering optimal healthcare experiences to our community, knowing that our employees, patients, and visitors are safe when they enter our facilities.”
The SmartGateway will soon be available at multiple Community hospitals including Community Hospital North, Community Behavioral Health, Community Fairbanks Recovery Center, Community Heart and Vascular Hospital, Community Hospital East, Community Hospital South, Community Hospital Anderson, and Community Howard Regional Health.